Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neutropenia 1Neoplasms 1Breast Neoplasms 1

Interventions

pegfilgrastim 22Filgrastim 11Cyclophosphamide 7Docetaxel 6eflapegrastim 4pegylated granulocyte colony-stimulating factor 3Vancomycin 2Itraconazole 2Granulocyte Colony-Stimulating Factor 2Fluorouracil 2Doxorubicin 2posaconazole 1ceftobiprole medocaril 1angiotensin I (1-7) 1Teicoplanin 1Sodium Chloride 1Oxaliplatin 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Methotrexate 1Maxy G34 1Mannose-Binding Lectin 1MYL-1401H 1Leucovorin 1Fluconazole 1EC regimen 1Diet, High-Fat 1Cefepime 1Bevacizumab 1Amphotericin B 11-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neutropenia × Maxy G34 × Clear all
NCT00501332 2007-12-24

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

Maxygen Holdings Ltd.

Phase 2 Unknown
30 enrolled
Breast

Breast Neoplasms, Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡